See more : Central Pacific Financial Corp. (CPF) Income Statement Analysis – Financial Results
Complete financial analysis of Amryt Pharma plc (AMYT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amryt Pharma plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Shin Nippon Biomedical Laboratories, Ltd. (2395.T) Income Statement Analysis – Financial Results
- Comperia.pl S.A. (CPL.WA) Income Statement Analysis – Financial Results
- Belden Inc. (BDC) Income Statement Analysis – Financial Results
- Secure, Inc. (4264.T) Income Statement Analysis – Financial Results
- Stockmann Oyj Abp (STOCKA.HE) Income Statement Analysis – Financial Results
Amryt Pharma plc (AMYT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.amrytpharma.com
About Amryt Pharma plc
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 222.54M | 182.61M | 58.12M | 16.53M | 15.33M | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 106.12M | 119.03M | 42.00M | 6.06M | 6.45M | 616.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 116.42M | 63.58M | 16.12M | 10.47M | 8.88M | 804.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 52.32% | 34.82% | 27.74% | 63.35% | 57.95% | 56.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 37.73M | 27.62M | 15.83M | 10.35M | 12.67M | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.34M | 4.73M | 841.00K | 17.57M | 13.25M | 4.25M | 3.33M | 2.93M | 1.87M | 275.37K | 281.22K | 1.72M | 1.74M | 3.05M | 2.33M |
| Selling & Marketing | 92.00M | 76.67M | 35.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.34M | 81.40M | 36.34M | 17.57M | 13.25M | 4.25M | 3.33M | 2.93M | 1.87M | 275.37K | 281.22K | 1.72M | 1.74M | 3.05M | 2.33M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.83K | -47.51K | 5.03K | 11.50K |
| Operating Expenses | 138.07M | 109.02M | 52.17M | 27.92M | 25.93M | 6.95M | 3.34M | 2.93M | 1.86M | 275.37K | 281.22K | 281.82K | 1.74M | 3.05M | 2.33M |
| Cost & Expenses | 244.18M | 228.05M | 94.17M | 33.98M | 32.37M | 7.57M | 3.34M | 2.93M | 1.86M | 275.37K | 281.22K | 281.82K | 1.74M | 3.05M | 2.33M |
| Interest Income | 5.00K | 87.00K | 92.00K | 5.72K | 6.00K | 1.05K | 185.00K | 201.00K | 319.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 27.91M | 19.57M | 8.48M | 1.78M | 989.75K | 127.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 50.74M | 44.47M | 12.63M | 354.61K | 310.72K | 204.03K | 6.00K | 6.00K | 4.56K | 0.00 | 99.63K | 147.69K | 144.69K | 224.23K | 161.09K |
| EBITDA | 29.10M | -977.00K | -23.42M | -17.09M | -16.73M | -5.94M | 33.26M | -3.10M | -1.27M | -275.37K | -281.22K | -281.82K | -1.60M | -2.83M | -2.17M |
| EBITDA Ratio | 13.08% | -0.54% | -40.29% | -103.36% | -109.16% | -418.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.64M | -45.44M | -36.04M | -17.44M | -17.04M | -8.08M | -39.93M | -2.93M | -3.51M | -275.37K | -281.22K | -281.82K | -459.87K | -3.28M | -2.43M |
| Operating Income Ratio | -9.72% | -24.89% | -62.01% | -105.51% | -111.18% | -568.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.17M | -60.42M | -30.72M | -12.00M | -14.31M | -127.26K | 189.00K | -36.81M | 376.00K | -1.84M | -5.85K | 0.00 | -63.03K | 7.94K | 14.28K |
| Income Before Tax | -29.81M | -105.86M | -66.76M | -29.45M | -31.36M | -8.21M | -39.74M | -2.56M | -2.12M | -275.37K | -281.22K | -281.82K | -522.90K | -3.27M | -2.41M |
| Income Before Tax Ratio | -13.40% | -57.97% | -114.86% | -178.09% | -204.54% | -577.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -11.64M | -1.33M | -1.23M | 41.18K | 14.31M | 1.93M | 73.18M | -175.00K | 2.23M | 550.74K | 2.68M | 1.51K | -25.79K | 226.22K | 101.27K |
| Net Income | -18.17M | -104.53M | -65.54M | -29.49M | -45.67M | -8.21M | -39.74M | -2.56M | -2.12M | -826.12K | -3.06M | -123.58K | -497.11K | -3.27M | -2.41M |
| Net Income Ratio | -8.17% | -57.24% | -112.75% | -178.34% | -297.89% | -577.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.39 | -2.92 | -4.32 | -3.22 | -6.14 | -1.51 | -3.45 | -0.26 | -0.33 | -0.08 | -0.30 | -0.01 | -0.05 | -0.42 | 0.00 |
| EPS Diluted | -0.37 | -2.92 | -4.32 | -3.22 | -6.14 | -1.51 | -3.45 | -0.26 | -0.33 | -0.08 | -0.30 | -0.01 | -0.05 | -0.42 | 0.00 |
| Weighted Avg Shares Out | 47.17M | 35.76M | 15.17M | 9.16M | 7.44M | 5.44M | 11.51M | 9.81M | 6.47M | 10.12M | 10.12M | 10.12M | 9.59M | 7.87M | 0.00 |
| Weighted Avg Shares Out (Dil) | 49.40M | 35.76M | 15.17M | 9.16M | 7.44M | 5.44M | 11.51M | 9.81M | 6.47M | 10.12M | 10.12M | 10.12M | 9.59M | 7.87M | 0.00 |
Amryt Pharma hopeful of winning fast-track US approval for breakthrough skin gel
Amryt Pharma completes FDA submission process for breakthrough skin gel; applies for expedited approval
Amryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
Amryt Pharma encouraged by study of lomitapide in Familial Chylomicronaemia Syndrome
Amryt Pharma encouraged by data from investigator-sponsored study assessment of lomitapide in Familial Chylomicronaemia Syndrome
Amryt Pharma's skin disorder treatment approved for EU regulatory review process
Amryt Pharma receives positive feedback from the US Food & Drug Administration regarding Myalept
Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
Amryt Pharma says it will receive reimbursement for Myalepta in France
Source: https://incomestatements.info
Category: Stock Reports